NMN Clinical Studies

Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men

Finding: NMN overall safely and effectively boosted NAD+ biosynthesis in healthy, middle-aged Japanese men, showing its potential for alleviating postprandial hyperinsulinemia.

Nicotinamide mononucleotide (NMN) intake increases plasma NMN and insulin levels in healthy subjects

Finding: Oral administration of NMN elevates plasma levels of NMN and NAD+, and postprandial serum insulin levels.

Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study

Finding: NMN administration in overweight or obese, middle-aged and older adults safely increased circulating NAD levels, and significantly reduced total LDL and non-HDL cholesterol, body weight, and diastolic blood pressure. 

Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial

Finding: NMN supplementation may alleviate vascular stiffness and reduce the risk of cardiovascular diseases events.

1,000mg

2,000mg

MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults

Finding: MIB-626 1 000 mg once-daily or twice-daily regimens were safe and associated with substantial dose-related increases in blood NAD levels and its metabolome.

300mg

600mg

900mg

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial

Finding: Oral administration of NMN up to 900 mg/day for 60 days was safe and well tolerated. NMN supplementation had a positive impact on the physical endurance and general health conditions of healthy adults.

Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind study

Finding: In older male patients with diabetes and impaired physical performance, NMN supplementation for 24 weeks was safe, but did not improve grip strength and walking speed.

Nicotinamide Mononucleotide Is Safely Metabolized and Significantly Reduces Blood Triglyceride Levels in Healthy Individuals

Finding: NMN administration significantly increased blood NAD+ levels without damaging blood cells and significantly reduced blood triglyceride (TG) levels. These findings imply that intravenous administration of NMN may lead to the prevention and treatment of diseases associated with increased TG levels, such as fatty liver and diabetes.

Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women

Finding: Our results indicate that β-NMN is safe and well-tolerated in healthy adult men and women an oral dose of 1250 mg once daily for up to 4 weeks.

Clinical evaluation of changes in biomarkers by oral intake of NMN

Finding: NMN 300 mg/day orally for eight weeks showed no safety issues and favorable changes in many biomarkers,
suggesting that NMN, a member of the NAD world, may be a promising nutritional material for aging and metabolic control
in humans.

Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men

Finding: Chronic oral NMN supplementation can be an efficient NAD + booster for preventing aging-related muscle dysfunctions in humans.

A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults

Finding: The rise in the levels of NAD+/NADH at day 30 and day 60 illustrated the potential of Uthever to raise the levels of NAD+ in the cells, which is linked to higher energy levels and an anti-aging effect. Increased sensitivity to insulin has also been linked to anti-aging.

Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects

Finding: Oral administration of NMN can be a practical strategy to boost NAD+ levels in humans.

Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study

Finding: NMN intake in the afternoon is more effective in improving lower limb function and reducing drowsiness in older adults, which could further benefit their physical and mental health.

300mg

600mg

1,200mg

Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study

Finding: NMN increases the aerobic capacity of humans during exercise training, and the improvement is likely the result of enhanced O2 utilization of the skeletal muscle.

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

Finding: The results from our study demonstrate that NMN supplementation (250 mg/day) increases skeletal muscle insulin signaling, insulin sensitivity, and muscle remodeling in postmenopausal women with prediabetes who are overweight or obese.

100mg

250mg

500mg

Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men

Finding: Oral administration of NMN was found to be feasible, implicating a potential therapeutic strategy to mitigate aging-related disorders in humans.